4//SEC Filing
Detke Michael J. 4
Accession 0001209191-21-045948
CIK 0001662774other
Filed
Jul 6, 8:00 PM ET
Accepted
Jul 7, 8:38 PM ET
Size
26.9 KB
Accession
0001209191-21-045948
Insider Transaction Report
Form 4
Cortexyme, Inc.CRTX
Detke Michael J.
Chief Medical Officer
Transactions
- Sale
Common Stock
2021-07-07$56.99/sh−523$29,806→ 0 total - Exercise/Conversion
Common Stock
2021-07-06$2.23/sh+12,600$28,098→ 40,861 total - Sale
Common Stock
2021-07-06$53.91/sh−8,260$445,297→ 288 total - Sale
Common Stock
2021-07-06$55.01/sh−288$15,843→ 0 total - Exercise/Conversion
Common Stock
2021-07-07$2.23/sh+17,400$38,802→ 17,400 total - Sale
Common Stock
2021-07-07$54.37/sh−1,648$89,602→ 11,818 total - Sale
Common Stock
2021-07-07$56.27/sh−6,942$390,626→ 523 total - Exercise/Conversion
Stock Option (right to buy)
2021-07-07−17,400→ 102,352 totalExercise: $2.23Exp: 2028-11-27→ Common Stock (17,400 underlying) - Sale
Common Stock
2021-07-06$53.43/sh−32,313$1,726,484→ 8,548 total - Sale
Common Stock
2021-07-07$53.24/sh−3,934$209,446→ 13,466 total - Sale
Common Stock
2021-07-07$55.38/sh−4,353$241,069→ 7,465 total - Exercise/Conversion
Stock Option (right to buy)
2021-07-06−12,600→ 119,752 totalExercise: $2.23Exp: 2028-11-27→ Common Stock (12,600 underlying)
Footnotes (9)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2021.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.69 to $53.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.71 to $54.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.745 to $53.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.75 to $54.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.79 to $55.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.80 to $56.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.81 to $57.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F9]The option will vest as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022.
Documents
Issuer
Cortexyme, Inc.
CIK 0001662774
Entity typeother
Related Parties
1- filerCIK 0001770786
Filing Metadata
- Form type
- 4
- Filed
- Jul 6, 8:00 PM ET
- Accepted
- Jul 7, 8:38 PM ET
- Size
- 26.9 KB